stock here: transcript

Testimony on Vaccine Safety, Myocarditis Risks, and Data Transparency

Table of Contents

• Chapter 1: Concerns Over Vaccine Safety
• Chapter 2: Introduction of Dr. Peter McCullough
• Chapter 3: Cardiac Risks and Vaccine-Induced Myocarditis
• Chapter 4: VAERS Data and Patient Impact
• Chapter 5: Mechanism of Harm and Evaluating Efficacy

Chapter 1: Concerns Over Vaccine Safety

Eighty percent of Americans took a COVID-19 vaccine; twenty percent did not. The vaccine was never safe enough for me to take.

Messenger RNA devised by Pfizer and Moderna was chemically modified to be resistant to the enzymes in the human body that would normally break it down. As a result, messenger RNA has been identified in the human hearts of individuals who died following vaccination, as well as in the brain. Furthermore, the spike protein is distributed throughout the body. Three independent studies now demonstrate that the spike protein circulates in the bloodstream for six to nine months post-vaccination.

In vaccinated individuals, this portion of the virus—the lethal component—remains in circulation. When individuals receive subsequent boosters, additional spike protein enters circulation. It functions as a killer protein; it cannot be considered safe, and it was unsafe by design. Safety must always trump efficacy. We cannot tolerate false drug claims. This data is established in peer-reviewed literature and does not constitute misinformation.

Chapter 2: Introduction of Dr. Peter McCullough

Chairman: Our first witness is Dr. Peter McCullough. Dr. McCullough is an internist, cardiologist, and epidemiologist based in Dallas, Texas. He has published extensively, with over 700 citations indexed in the National Library of Medicine. He has testified on multiple occasions before the U.S. Senate, the U.S. House of Representatives, the European Parliament, and numerous state legislatures regarding public health policy. Dr. McCullough, welcome.

Dr. Peter McCullough: Chairman Johnson, Ranking Member Blumenthal, and members of the subcommittee, it is an honor to present my insights, analysis, and clinical experience on this critical topic.

The first time I testified before the Senate Committee on Homeland Security and Governmental Affairs, before I uttered a single word, Ranking Member Senator Gary Peters stated that what the American public was about to hear was “misinformation.” I did not understand the framing at the time; I had never encountered that term used in academic medicine or high-level policy deliberations. That was on November 19, 2020.

In effect, he was employing an established political tactic to discredit my testimony before I spoke. Public officials should not seek leverage over experts coming to Washington to assist the nation on critical issues. As introduced, I am an internist and cardiologist, and I believe I am among the most published individuals to testify on COVID-19 matters in these legislative hearings.

Chapter 3: Cardiac Risks and Vaccine-Induced Myocarditis

I have examined thousands of patients, analyzed extensive dataset collections, and published extensively on this subject. As a physician and cardiologist, my professional imperative has always been to fight disease, preserve life, and above all, do no harm.

Our focus today is myocarditis—heart muscle inflammation and damage—resulting from COVID-19 vaccines. Prior to the pandemic, I had evaluated only two cases of myocarditis across my entire clinical career. Today, there are over 1,650 peer-reviewed papers documenting COVID-19 vaccine-induced myocarditis.

Allow me to summarize key findings from the peer-reviewed literature:

1. Washington University in St. Louis (August 18, 2021): Published in the New England Journal of Medicine by Verma et al., a 42-year-old male was admitted to Washington University Hospital with vaccine-associated myocarditis. Viral infection was ruled out. Despite receiving care at a leading medical center, he died three days after receiving the Moderna vaccine.
2. South Korean Study: Reported by Choi et al., a young male presented to the hospital shortly after receiving the Pfizer vaccine. He died within eight hours of admission—an acute rate of mortality rarely observed even in severe heart attacks. Histopathological examination showed extensive, severe tissue inflammation throughout the myocardium.
3. Connecticut Case Series: Published in the Archives of Pathology & Laboratory Medicine by Gill et al., two teenage boys (ages 16 and 17) died several days after receiving the Pfizer vaccine. Both were found deceased at home. Autopsies conducted with input from pathology teams at the University of Michigan and the University of Minnesota definitively identified Pfizer COVID-19 vaccine-induced myocarditis as the cause of death.

These autopsy-confirmed findings are documented in peer-reviewed literature and demand rigorous medical scrutiny.

Chapter 4: VAERS Data and Patient Impact

We must evaluate the biological mechanism driving these outcomes. The mRNA formulations from Pfizer and Moderna, alongside the viral vector platform from Janssen, instruct cells to synthesize the viral spike protein. This protein acts as an agent of cellular damage when systemically distributed. While acute myocarditis exhibits variations based on genetic predisposition and batch variations, ongoing vaccination campaigns inherently carry a risk of acute myocarditis cases.

Data from the Vaccine Adverse Event Reporting System (VAERS) reflects a significant shift in reporting patterns:

Historical Baseline vs. COVID-19 Era Reporting (VAERS Data)
---------------------------------------------------------------------------------
Pre-2021 Average:    ~200–300 reported deaths annually (all vaccines combined)
Cumulative Post-2021: 38,670+ reported deaths worldwide associated with COVID shots
Immediate Onset:     9,228 reported deaths occurred within 0–2 days of injection

While VAERS reports represent raw observational signals rather than definitive proof of causal link, the temporal cluster requires formal investigation. Furthermore, many individuals reporting post-vaccination health changes have struggled to secure clinical acknowledgment or targeted treatment protocols from health institutions.

Patients suffering long-term post-vaccination complications require objective medical evaluation, empathetic clinical care, and targeted therapeutics rather than dismissal.

Chapter 5: Mechanism of Harm and Evaluating Efficacy

The synthetic messenger RNA used in these platforms was engineered with modified nucleosides to increase durability and resist enzymatic degradation. Consequently, both mRNA and spike proteins have been detected across multiple organ systems—including cardiac tissue, brain tissue, and vascular beds—for extended periods post-injection. Studies indicate circulating spike protein remains in the blood six to nine months following administration, with subsequent boosters re-introducing additional load.

Regarding population-level outcomes and claims that the vaccines saved millions of lives: prospective, randomized, double-blind, placebo-controlled clinical trials demonstrated efficacy against symptomatic infection initially, but were not designed or powered to demonstrate reductions in all-cause mortality or hospitalization over extended periods.

The overall reduction in COVID-19 mortality over the course of the pandemic can be attributed to three primary factors:

1. Natural Immunity: The widespread acquisition of naturally acquired post-infection immunity across both vaccinated and unvaccinated populations.
2. Early Outpatient Treatment: The development and deployment of early multi-drug protocols and therapeutic interventions that managed patients at home, reducing emergency room visits and hospital admissions.
3. Viral Evolution: The natural mutation of the SARS-CoV-2 virus into milder, less lethal variants (such as the Omicron lineages).

Public health claims and regulatory messaging must remain grounded in rigorous clinical evidence, transparent safety surveillance, and verifiable data.